
Articles
-
5 days ago |
medicalnewstoday.com | Paul Ian Cross
Share on PinterestA novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in a large, diverse group of patients who had not responded to other medications. These findings mark a significant step forward in the development of the first targeted aldosterone synthase inhibitor for these conditions.
-
5 days ago |
aol.com | Paul Ian Cross
A novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase inhibitor, safely and consistently lowered blood pressure in a large, diverse group of patients who had not responded to other medications. These findings mark a significant step forward in the development of the first targeted aldosterone synthase inhibitor for these conditions.
-
2 weeks ago |
medicalnewstoday.com | Paul Ian Cross
Share on PinterestA new study from UC San Francisco may offer the first clear biological markers for frontotemporal dementia, a condition that often affects people in midlife and is difficult to diagnose. By analysing spinal fluid from patients with inherited frontotemporal dementia, researchers uncovered protein changes linked to RNA regulation and brain connectivity; early indicators that could lead to earlier, more accurate diagnosis.
-
2 weeks ago |
resources.healthgrades.com | Paul Ian Cross
A new study from UC San Francisco may offer the first clear biological markers for frontotemporal dementia, a condition that often affects people in midlife and is difficult to diagnose. By analysing spinal fluid from patients with inherited frontotemporal dementia, researchers uncovered protein changes linked to RNA regulation and brain connectivity; early indicators that could lead to earlier, more accurate diagnosis.
-
3 weeks ago |
medicalnewstoday.com | Paul Ian Cross
Share on PinterestResearchers at UVA Health have found that a class of HIV drugs called nucleotide reverse transcriptase inhibitors (NRTIs) may significantly reduce the risk of developing Alzheimer’s disease. Their large-scale analysis of United States health insurance data revealed that patients taking these medications had up to a 13% lower risk of Alzheimer’s disease each year.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →